Alexion to start Soliris in COVID-19 Phase II trial in next few days
By MYBRANDBOOK
Alexion Pharmaceuticals is revving up to enter the COVID-19 drug development race with Soliris (eculizumab), a drug that is already approved for other indications, a source familiar with the trial told Reynald Castañeda, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company.
Castañeda comments: “The source explained that the idea behind Soliris is that the drug impacts the complement system, which could help reduce organ damage in severe COVID-19 patients.”
When asked to comment, an Alexion spokesperson pointed Castañeda to a media release stating how the company is interested in the potential use of Soliris in COVID-19 due to preclinical rationale that suggests it could be used in a subset of patients who have coronaviral infection and severe pneumonia or acute respiratory distress syndrome. Alexion is providing Soliris for experimental emergency treatment for a small number of patients with COVID-19 infection and severe pneumonia, it states.
Soliris made $3.95bn in 2019, as per SEC filings. It was first approved by the US Food and Drug Administration (FDA) in May 2007 for the rare blood disease paroxysmal nocturnal hemoglobinuria and subsequently approved in haemolytic uremic syndrome and myasthenia gravis in September 2011 and October 2017, respectively.
Castañeda continues: “This planned COVID-19 Phase II study is on the heels of a ten-patient, single-site, proof-of-concept trial, which started ten days ago, and data is expected to be revealed sometime this week, the source noted. While he declined to detail the status of these ten patients, he noted the patients improved in general.”
GlobalData’s COVID-19 Intelligence Dashboard shows that there are 623 clinical trials across the globe that are either planned or ongoing.
BHIM to join e-commerce, competing with PhonePe and Google Pay
The government-supported payment software BHIM is getting ready to join t...
The latest version of X helps prevent deepfakes on social medi
To combat deepfakes and shallowfakes, Elon Musk revealed a new update t...
India and Namibia collaborate on a payment system similar to U
Once operational, the platform will enable digital transactions in Namibia,...
Sebi issues show-cause notices to six Adani group firms
Sebi issued show-cause notices to six Adani Group firms, including Adani ...
MICROTEK INTERNATIONAL PVT. LTD.
CP PLUS INDIA PVT. LTD.
RAMCO SYSTEMS Ltd.
AMARA RAJA POWER SYSTEMS LTD.
Technology Icons Of India 2023: Sridhar Vembu
Sridhar Vembu is an Indian billionaire business magnate and the Founde...
Technology Icons Of India 2023: Madhabi Puri Buch
Madhabi Puri Buch is the chairperson of the securities regulatory body...
Technology Icons Of India 2023: Shailendra Katyal
Shailendra is instrumental in Lenovo achieving the no.1 position in PC...
HPCL is transforming the energy landscape, across the nation and beyond
HPCL is world-class energy company known for caring and delighting the...
GSTN aims to integrate indirect tax ecosystem on a shared IT infrastructure
Goods and Services Tax Network (GSTN) has built Indirect Taxation plat...
INDIANOIL helps reach precious petroleum fuels to every nook and corner of the country
IndianOil, a diversified, integrated energy major with presence in alm...
TECH DATA, A TD SYNNEX COMPANY
Tech Data Corporation was an American multinational distribution compa...
EXCLUSIVE NETWORKS SALES INDIA PVT. LTD.
Exclusive Networks is a globally trusted cybersecurity specialist hel...
INGRAM MICRO INDIA PVT. LTD.
Ingram Micro India, a large national distributor offers a comprehensiv...